Cargando…

Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials

Keratoconjunctivitis sicca, also known as dry eye disease (DED), is a prevalent, multifactorial disease associated with compromised ocular lubrication, ocular surface inflammation and damage, and ocular symptoms. Several anti-inflammatory, topical ophthalmic therapies are available to treat clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen Lee, Bridgitte, Toyos, Melissa, Karpecki, Paul, Schiffbauer, Jessica, Sheppard, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253213/ https://www.ncbi.nlm.nih.gov/pubmed/35608780 http://dx.doi.org/10.1007/s40123-022-00516-9

Ejemplares similares

Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
por: Shen Lee, Bridgitte, et al.
Publicado: (2020)

Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists
por: Sheppard, John, et al.
Publicado: (2022)

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease
por: Nichols, Kelly K, et al.
Publicado: (2018)

Results from a Prospective, Open-Label, Phase 4 Pilot Study of Repository Corticotropin Injection for Moderate and Severe Dry Eye Disease
por: Toyos, Melissa, et al.
Publicado: (2022)

The Relationship Between Dry Eye Disease and Digital Screen Use
por: Al-Mohtaseb, Zaina, et al.
Publicado: (2021)

Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study
por: Toyos, Rolando, et al.
Publicado: (2022)

LIFITEGRAST 5% FOR DRY EYE DISEASE: COMBINED EFFICACY AND SAFETY FROM FIVE RANDOMIZED CONTROLLED TRIALS
por: Gonzalez, Agustin L, et al.
Publicado: (2019)

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
por: McMullin, David, et al.
Publicado: (2021)

Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
por: Sheppard, John, et al.
Publicado: (2021)

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
por: Tauber, Joseph, et al.
Publicado: (2018)

Does Dry Eye Disease Severity Impact Efficacy of Varenicline Solution Nasal Spray on Sign and Symptom Treatment Outcomes?
por: Sheppard, John D., et al.
Publicado: (2023)

Safety and Tolerability of an Eye Drop Based on 0.6% Povidone–Iodine Nanoemulsion in Dry Eye Patients
por: Oliverio, Giovanni William, et al.
Publicado: (2021)

A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments
por: Periman, Laura M, et al.
Publicado: (2020)

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study
por: Donnenfeld, Eric D., et al.
Publicado: (2016)

Effect of Oral Re-esterified Omega-3 Nutritional Supplementation on Dry Eyes
por: Epitropoulos, Alice T., et al.
Publicado: (2016)

Ocular Pharmacological Profile of Hydrocortisone in Dry Eye Disease
por: Bucolo, Claudio, et al.
Publicado: (2019)

An evaluation of Retaine™ ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eye
por: Ousler, George, et al.
Publicado: (2015)

Safety and Efficacy of Cyclosporine in the Treatment of Chronic Dry Eye
por: Schultz, Clyde
Publicado: (2014)

Clinical Efficacy, Tolerability and Safety of a New Multiple-Action Eyedrop in Subjects with Moderate to Severe Dry Eye
por: Roszkowska, Anna Maria, et al.
Publicado: (2022)

A Prospective, Post-Market, Multicenter Trial (CHEETAH) Suggested TearCare(®) System as a Safe and Effective Blink-Assisted Eyelid Device for the Treatment of Dry Eye Disease
por: Karpecki, Paul, et al.
Publicado: (2020)

A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease
por: Tauber, Joseph, et al.
Publicado: (2021)

Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial
por: Schechter, Barry A, et al.
Publicado: (2022)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White, Darrell E, et al.
Publicado: (2019)

Novel Extranasal Tear Stimulation: Pivotal Study Results
por: Ji, Marco H., et al.
Publicado: (2020)

Evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye
por: Torkildsen, Gail, et al.
Publicado: (2017)

A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease
por: Wirta, David L., et al.
Publicado: (2019)

Reduction of Artificial Tears and Use of Adjunctive Dry Eye Therapies After Lifitegrast Treatment: Evidence from Clinical and Real-World Studies
por: Nichols, Kelly K, et al.
Publicado: (2022)

Randomized controlled trial on the efficacy and safety of autologous serum eye drops in dry eye syndrome
por: Zheng, Na, et al.
Publicado: (2023)

Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease
por: Yeu, Elizabeth, et al.
Publicado: (2019)

TearCare for the Treatment of Meibomian Gland Dysfunction in Adult Patients With Dry Eye Disease: A Masked Randomized Controlled Trial
por: Gupta, Preeya K., et al.
Publicado: (2022)

Cyclosporine Lipid Nanocapsules as Thermoresponsive Gel for Dry Eye Management: Promising Corneal Mucoadhesion, Biodistribution and Preclinical Efficacy in Rabbits
por: Eldesouky, Lubna M., et al.
Publicado: (2021)

Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1)
por: Yeu, Elizabeth, et al.
Publicado: (2023)

Preclinical pharmacology, efficacy, and safety of varenicline in smoking cessation and clinical utility in high risk patients
por: Xi, Zheng-Xiong
Publicado: (2010)

Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment
por: Geerling, Gerd, et al.
Publicado: (2022)

Transitions and Instabilities in Imperfect Ion-Selective Membranes
por: Schiffbauer, Jarrod, et al.
Publicado: (2020)

A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease
por: Clark, David, et al.
Publicado: (2021)

Toxic effects of selected proprietary dry eye drops on Acanthamoeba
por: Sifaoui, Ines, et al.
Publicado: (2018)

Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes
por: McLaughlin, Patricia J., et al.
Publicado: (2019)

Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
por: Karpecki, Paul, et al.
Publicado: (2023)

Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic Landscape
por: Sheppard, John D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n3qef93c31vdk37e6n2ra8atcg